Lymphoma (cont.)
Medical Author:
Jerry R. Balentine, DO, FACEP
Jerry R. Balentine, DO, FACEPDr. Balentine received his undergraduate degree from McDaniel College in Westminster, Maryland. He attended medical school at the Philadelphia College of Osteopathic Medicine graduating in1983. He completed his internship at St. Joseph's Hospital in Philadelphia and his Emergency Medicine residency at Lincoln Medical and Mental Health Center in the Bronx, where he served as chief resident. Medical Editor:
Melissa Conrad Stöppler, MD, Chief Medical Editor
Melissa Conrad Stöppler, MD, Chief Medical EditorMelissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology. IN THIS ARTICLE
Lymphoma DiagnosisIf a person has swelling or symptoms described in the Symptoms section, his or her health-care provider will ask many questions about the symptoms (when they began, recent illnesses, past or current medical problems, any medications, workplace, health history, family history, and habits and lifestyle). These questions are followed by a thorough examination. If, after an initial interview and examination, the health-care provider suspects that a patient may have lymphoma, the patient will undergo a series of tests designed to provide further clarification. At some point in this workup, the patient will likely be referred to a specialist in blood diseases and cancer (hematologist/oncologist). Blood tests Blood is drawn for various tests.
Biopsy If there is a swelling (also called lump or mass), a sample of tissue from the swelling will be removed for examination by a pathologist. This is called a biopsy. Any of several methods can be used to obtain a biopsy of a mass.
Imaging studies If there is no palpable mass in the presence of persistent symptoms, imaging studies will likely be carried out in order to determine whether a mass is present and, if so, how then to direct a biopsy.
Bone marrow examination Most of the time, an examination of the bone marrow is necessary to see if the marrow is affected by the lymphoma. This is done by collecting a biopsy of the bone marrow.
Other tests
Staging Staging is the classification of a cancer type by its size and whether and how much it has spread around the body. Determining a cancer's stage is very important because it tells the oncologist which treatment is most likely to work and what are the chances of remission or a cure (prognosis). Staging of lymphomas is based on the results of imaging studies and related tests that reveal the extent of the cancer involvement. HL is often described as being "bulky" or "nonbulky." Nonbulky means the tumor is small; bulky means the tumor is large. Nonbulky disease has a better prognosis than bulky disease. NHL is a complicated set of diseases with a complex classification system. In fact, the classification system is continuously evolving as we learn more about these cancers. The newest classification system takes into account not only the microscopic appearance of the lymphoma but also its location in the body and genetic and molecular features. Grade is also an important component of the NHL classification.
The "staging," or evaluation of extent of disease, for both HL and NHL, are similar.
Both HL and NHL are further classified with letters.
Prognostic factors Several risk factors have been extensively evaluated and shown to play a role in treatment outcome. For HL, the International Prognostic Index includes the following seven risk factors:
The absence of any of the above risk factors is associated with an 84% rate of control of Hodgkin's disease, whereas the presence of a risk factor is associated with a 77% rate of disease control. The presence of five or more risk factors was associated with a disease control rate of only 42%. The outcomes for these patients were also determined by the treatment they received, which occurred primarily in the 1980s. Newer treatments for Hodgkin's lymphoma may improve these predicted outcomes. Furthermore, new treatments are being developed for patients with greater risk factors. The International Prognostic Index for NHL includes five risk factors:
The prognostic models were developed to evaluate groups of patients and are useful in developing therapeutic strategies. It is important to remember that any individual patient might have significantly different results than the above data, which represent statistical results for a patient group. Viewer Comments & ReviewsLymphoma - Effective TreatmentThe eMedicineHealth physician editors ask:What treatment has been effective for your lymphoma? Lymphoma - Symptoms at Onset of DiseaseThe eMedicineHealth physician editors asked:Lymphoma symptoms can vary greatly from patient to patient. What were your symptoms at the onset of your disease? |
Women's Health
Find out what women really need.
From WebMD
Cancer Resources
Featured Centers
- Ask the Nutritionist: Weight Loss Tips
- Which Drugstore Tooth Whiteners Work Best?
- Gout: Symptoms, Causes, and Treatments
Health Solutions From Our Sponsors
Read What Your Physician is Reading on Medscape
Lymphoma, B-Cell »
Non-Hodgkin lymphoma (NHL) is a heterogenous group of lymphoproliferative malignancies with differing patterns of behavior and responses to treatment (Armitage, 1993).
Featured Topics
Medical Dictionary
Pill Identifier on RxList
- quick,
easy,
pill identification
Find a Local Pharmacy
- including
24 hour
pharmacies

